Table 2.
Serum Osteopontin and Osteoprotegerin in the studied groups
| RA (n = 20) |
FDRs (n = 25) |
Controls (n = 10) |
P | |
|---|---|---|---|---|
| Serum OPN (ng/ml) | ||||
| Min. – Max. | 0.0–18.40 | 0.90–5.80 | 1.40–5.40 | 0.102 |
| Mean ± SD. | 3.66 ± 4.20 | 1.97 ± 1.04 | 2.81 ± 1.31 | |
| Median | 2.50 | 1.80 | 2.65 | |
| Serum OPG (pg/ml) | ||||
| Min. – Max. | 0.0–1558.0 | 0.0–334.1 | 0.0–39.80 | 0.004* |
| Mean ± SD. | 143.89 ± 365.47 | 22.23 ± 65.73 | 6.20 ± 12.43 | |
| Median | 21.20 | 7.70 | 1.50 | |
| Significance between groups | p1 = 0.009*, p2 = 0.003*, p3 = 0.332 | |||
p value for Kruskal Wallis test for comparing between the different groups; Significance between groups was done using Mann Whitney test; p1: p value for comparing between RA patients and FDRs; p2: p value for comparing between RA patients and controls; p3: p value for comparing between FDRs and controls; *: Statistically significant at p ≤ 0.05
RA: rheumatoid arthritis; FDRs: first degree relatives; OPN: Osteopontin; OPG: Osteoprotegerin